pages:
-
Advanced Education Nursing Traineeship (AENT) Program
-
Advanced Education Nursing Traineeship Program
-
Advanced Education Nursing Traineeship Program
-
Advanced Hazmat Life Support Toxic Terrorism Course
-
Advanced Hazmat Life Toxic Terrorism Support Course
-
Advanced Illness and Multimorbidity (AIM) Research Program
-
Advanced Nursing Education Grants
-
Advanced Technology to Study Visual Function on a Cellular Scale
-
Advanced Technology to Study Visual Function on a Cellular Scale
-
Advances in Perinatal Education in 2015
-
Advancing a Formal Multidisciplinary Surgical Simulation Curriculum through High Fidelity Laparoscopic Simulation
-
ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network
-
Advancing Autism Practices in Alabama
-
Advancing B.Sc. in Engineering Students in Hybrid-Electric and Electric Vehicles
-
Advancing Clinical Trials in Neonatal Opioid Withdrawal Syndrome (ACT NOW) Longitudinal Study Consortium To Carry Out The Outcomes of Babies with Opioid Exposure (OBOE) Study.
-
Advancing Health Equity
-
Advancing Health Equity in Jefferson County II
-
Advancing Health Equity in Jefferson County, AL
-
Advancing PINK1 KO Rat Animal Models of PD
-
Advancing PINK1 KO Rat Animal Models of PD
-
Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2
-
Advancing to a Phase 2 Clinical Trial for Pediatric Brain Tumors
-
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
pages:
